Comment on Li et al. BDP1 Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study. Diagnostics 2021, 11, 2364
- PMID: 35328161
- PMCID: PMC8947690
- DOI: 10.3390/diagnostics12030608
Comment on Li et al. BDP1 Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study. Diagnostics 2021, 11, 2364
Abstract
In 2021, Li et al. published an article on BDP1 variants and implications in pediatric neuroblastoma patients [...].
Conflict of interest statement
The author declares no conflict of interest.
Comment on
- Diagnostics (Basel). 11:2364.
Similar articles
-
Reply to Schramm, L. Comment on "Li et al. BDP1 Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study. Diagnostics 2021, 11, 2364".Diagnostics (Basel). 2022 Mar 2;12(3):617. doi: 10.3390/diagnostics12030617. Diagnostics (Basel). 2022. PMID: 35328170 Free PMC article.
-
BDP1 Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study.Diagnostics (Basel). 2021 Dec 15;11(12):2364. doi: 10.3390/diagnostics11122364. Diagnostics (Basel). 2021. PMID: 34943600 Free PMC article.
-
Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.BMC Syst Biol. 2017 Oct 3;11(Suppl 5):92. doi: 10.1186/s12918-017-0466-5. BMC Syst Biol. 2017. PMID: 28984200 Free PMC article.
-
The efficacy of procalcitonin as a biomarker in the management of sepsis: slaying dragons or tilting at windmills?Surg Infect (Larchmt). 2013 Dec;14(6):489-511. doi: 10.1089/sur.2012.028. Epub 2013 Nov 25. Surg Infect (Larchmt). 2013. PMID: 24274059 Review.
-
The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.Pediatr Surg Int. 2013 Feb;29(2):101-19. doi: 10.1007/s00383-012-3239-7. Epub 2012 Dec 29. Pediatr Surg Int. 2013. PMID: 23274701 Free PMC article. Review.
Cited by
-
Reply to Schramm, L. Comment on "Li et al. BDP1 Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study. Diagnostics 2021, 11, 2364".Diagnostics (Basel). 2022 Mar 2;12(3):617. doi: 10.3390/diagnostics12030617. Diagnostics (Basel). 2022. PMID: 35328170 Free PMC article.
References
-
- Li X., Sun L., Stucky A., Tu L., Cai J., Chen X., Wu Z., Jiang X., Li S.C. BDP1 Variants I1264M and V1347M Significantly Associated with Clinical Outcomes of Pediatric Neuroblastoma Patients Imply a New Prognostic Biomarker: A 121-Patient Cancer Genome Study. Diagnostics. 2021;11:2364. doi: 10.3390/diagnostics11122364. - DOI - PMC - PubMed
-
- Kim Y.W., Wang H., Sures I., Lammers R., Martell K.J., Ullrich A. Characterization of the PEST family protein tyrosine phosphatase BDP1. Oncogene. 1996;13:2275–2279. - PubMed
LinkOut - more resources
Full Text Sources